Articles tagged with: Multiple Myeloma Research Foundation
NewsFlash »
Fred Hutchinson Cancer Center To Field Questions At The Beacon's Forums This Week – Dr. William Bensinger, myeloma expert at the Fred Hutchinson Cancer Center in Seattle, WA, will be be responding to medical questions posted in the Myeloma Beacon's forums this week. Readers who have not yet visited the Beacon's new myeloma discussion forums are encouraged to do so, as they already contain a number of informative postings about topics such as myeloma treatment options, managing treatment side effects, and alternative myeloma therapies.
Treanda Combination Therapy Enters Phase 1B/2 Trial For Multiple Myeloma – Last week, the Multiple Myeloma Research Consortium (MMRC) announced the start of a Phase 1B/2 clinical trial that will evaluate a combination of Treanda (bendamustine), Revlimid (lenalidomide) and dexamethasone (Decadron) in relapsed multiple myeloma patients. Treanda is already approved in Germany in combination with prednisone for the treatment of multiple myeloma. In the United States, the drug is approved for the treatment of chronic lymphocytic leukemia and certain lymphomas. For more information, see the MMRC press release or the clinical trial description.
MMRF Kicks Off Race For Research 5K Walk/Run Series – On April 25, the Multiple Myeloma Research Foundation (MMRF) will kick off its annual Race For Research 5K Walk/Run series to raise awareness and funds for multiple myeloma research. The events will take place in eight cities across the Unites States. The first one is scheduled for April 25 in San Francisco. For more information and registration details, see the MMRF Web site.
For a more detailed listing of myeloma-related events, please check the Myeloma Beacon Events Calendar.
NewsFlash »
Myeloma Experts From University Of Arkansas Answer Questions At The Myeloma Beacon Forums This Week – Dr. Bart Barlogie and Dr. Bijay Nair, myeloma experts from the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences will be answering medical questions posted to the forums at the Myeloma Beacon this week. Readers can post their questions and review answers from other myeloma experts by visiting the Myeloma Beacon Forums.
MMRF Grants Funding To Intellikine and Tragara Pharmaceuticals For Novel Myeloma Treatments – The Multiple Myeloma Research Foundation (MMRF) announced last week that it will award Intellikine and Tragara Pharmaceuticals, two biotech companies based in Southern California, with $1 million each for the development of two new compounds for the treatment of multiple myeloma. Intellikine’s INK128 and Tragara Pharmaceuticals’ TG02 have both shown potential for multiple myeloma in pre-clinical studies. For more information, please see the MMRF press release.
5th Annual “Music Against Myeloma” Fundraiser To Be Held In NYC – On April 22, special musical performances will take place during the 5th annual “Music Against Myeloma” fundraiser to the benefit of the International Myeloma Foundation. The event will take place at BLVD in New York City from 7 to 10 p.m. Advance tickets are $40. Please see the Music Against Myeloma Web site for additional information and to purchase tickets.
For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar.
NewsFlash »
Myeloma Experts Continue To Answer Questions At The Myeloma Beacon Forums – The Mayo Clinic, represented by myeloma expert Dr. Martha Lacy, will be answering medical questions posted to the forums at the Myeloma Beacon this week. Readers are encouraged to post their questions to the Myeloma Beacon Forums.
MannKind Receives MMRF Grant For Development Of New Myeloma Treatment – The Multiple Myeloma Research Foundation (MMRF) and MannKind, a biopharmaceutical company based in Valencia, CA, announced today that the MMRF will award MannKind $1 million for the development of a new compound for the treatment of multiple myeloma. The new compound, an IRE-1a inhibitor, inhibits growth of tumor cells, which may in turn make the cancer cells more susceptible to common myeloma treatments. The award is based on results from nonclinical studies. For more information, please see the MannKind press release.
The MMRF Holds Free Myeloma Symposium – On April 9, the Multiple Myeloma Research Foundation (MMRF) will hold a free educational symposium for multiple myeloma patients, their family members and caregivers about the latest advances and treatments in multiple myeloma. The event will take place at the Grand Hyatt in New York, NY from 10 a.m. to 4 p.m. Please see the MMRF Web site to register.
For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar.
NewsFlash »
Dr. Ken Anderson Elected Officer To American Society Of Hematology – Dr. Ken Anderson is one of five newly elected officers to the American Society of Hematology’s (ASH) Executive Committee. Dr. Anderson is a renowned hematologist specializing in the treatment of multiple myeloma. He will begin serving his four-year term in January 2010. For more information, please see the ASH press release.
Revlimid Covered By Australian Government – Revlimid (lenalidomide) is now listed for the treatment of myeloma on the Pharmaceutical Benefits Scheme, a list of drugs subsidized by the Australian government. Revlimid will be subsidized for the next four years at a cost of A$104 million (US$94 million). For more information, please visit the Investor Village Web site.
Potential New Myeloma Treatment Starts Phase 1 Trial Extension For AML – Innate Pharma received approval from the French Regulatory authorities to begin an extension of the Phase 1 trial with IPH 2101 in patients with acute myeloid leukemia (AML). The company recently also started Phase 2 clinical trials with IPH 2101 for multiple myeloma. For more information, please see the Innate Pharma press release (pdf).
MMRF Race For Research – On November 15, the Multiple Myeloma Research Foundation (MMRF) is sponsoring a 5K walk/run. It will be held in Alexandria, VA and will start at 7:30 a.m. The MMRF is looking for participants and sponsors. For more information, please visit the MMRF Web site.
For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar.
NewsFlash »
UAMS Receives $19.5 Million Grant For Multiple Myeloma Program – The Myeloma Institute at the University of Arkansas for Medical Sciences (UAMS) will receive $19.5 million over five years from the National Cancer Institute (NCI). The grant is the fourth renewal of continuous funding from the NCI and will allow for continued research on myeloma and the development of new treatments. For more information, please visit the UAMS Web site.
MMRF’s Fall Gala Raises Over $1.8 Million For Multiple Myeloma Research – The Multiple Myeloma Research Foundation (MMRF) raised more than $1.8 million at its annual Fall Gala. The funds will support myeloma research and the development of new treatments. For more information, please visit the MMRF Web site.
3rd Annual Comedy Celebration – The International Myeloma Foundation’s (IMF) 3rd annual Comedy Celebration will take place on November 7 at The Wilshire Ebell Theatre & Club in Los Angeles. It will benefit the Peter Boyle Memorial Fund and will feature Ray Romano, Jimmey Kimmel, and Bob Saget, along with many others. For more information, please visit the IMF Web site.
World Run Day – On November 8, a 5K run will take place in multiple locations around the world. Among the charities which will receive funds from donations is the Multiple Myeloma Research Foundation (MMRF). For more information, please visit the World Run Day Web site.
For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar.
NewsFlash »
FDA Requests Additional Information For Prolia Approval – Amgen Inc. announced on Monday that the U.S. Food and Drug Administration (FDA) has requested additional information needed for the agency to complete its review of Prolia (denosumab). Amgen has applied to the FDA to have Prolia approved for the treatment and prevention of postmenopausal osteoporosis. In its recent information request, the FDA asked Amgen for all updated Prolia safety data as well as more details about Amgen's proposed post-marketing surveillance program for Prolia. The Agency also informed Amgen that a new clinical trial program will be necessary for the FDA to be able to approve Prolia for the prevention of postmenopausal osteoporosis. Prolia is currently being tested in multiple myeloma patients to see if it can delay skeletal events (see related Beacon article). For more information, please see the Amgen press release.
Race For Research 5K Walk/Run – On November 1, the Multiple Myeloma Research Foundation will be sponsoring the Race for Research 5K Walk/Run in Atlanta, Georgia. Registration starts at 7 a.m. and the race beings at 8:30 a.m. The MMRF is looking for participants and donations for this event. For more information, please visit the MMRF Web site.
RHS Open – On November 2, the International Myeloma Foundation is holding the Inaugural RHS open in Mt. Pleasant, SC. This annual golf tournament is held in honor of IMF Board Member, Rich Saletan. For more information, to register, or to sponsor a golfer, please visit the IMF Web site.
For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar.
NewsFlash »
MMRF Fall Gala – On October 24, the Multiple Myeloma Research Foundation (MMRF) is hosting a Fall Gala at the Hyatt Regency in Greenwich, CT. The MMRF will honor Hoda Kotb, co-host of “Today” and correspondent on “Dateline NBC,” with the Spirit of Hope Award for her efforts in advancing cancer awareness. A reception will begin at 6 p.m., and dinner will be served at 7:30 p.m. Tickets are $275 each. For more information or to reserve seats, please visit the MMRF Web site.
New York City Marathon – On November 1, the Multiple Myeloma Research Foundation (MMRF) Marathon team will run in the ING New York City Marathon. The MMRF team is looking for donations to help reach this year's fundraising goal. The MMRF is also looking for participants for next year's NYC Marathon, which will take place on November 7, 2010. For more information or to register, please visit the NYC Marathon or MMRF Web sites.
For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar.
